Marc Fellous, MD Study Director Vice President of Medical Affairs
Kontakt
PMV Pharma Clinical Study Information Center Kontakt: Phone: (609) 235-4038 E-Mail: clinicaltrials@pmvpharma.com» Kontaktdaten anzeigen
Studienlocations (3 von 55)
Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg Heidelberg (Baden-Württemberg) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Martin Haag, MD» Ansprechpartner anzeigenUniversitätsklinikum Augsburg Augsburg (Bayern) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Rainer Claus, MD» Ansprechpartner anzeigenUniversitätsklinikum Frankfurt Frankfurt (Hessen) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Martin Sebastian, MD» Ansprechpartner anzeigen
Kinderonkologisches Zentrum Universitätsklinikum Essen Hufelandstraße 55 45147 Essen DeutschlandNoch nicht rekrutierend» Google-Maps Ansprechpartner: Marcel Wiesweg, MD» Ansprechpartner anzeigenAsklepios Klinik Altona Hamburg (Hamburg) GermanyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Dirk Arnold, MD» Ansprechpartner anzeigenCity of Hope 91010 Duarte United StatesNoch nicht rekrutierend» Google-Maps Ansprechpartner: Stephen Gruber, MD» Ansprechpartner anzeigenUniversity of California, San Diego 92093 La Jolla United StatesNoch nicht rekrutierend» Google-Maps Ansprechpartner: Shumei Kato, MD» Ansprechpartner anzeigenUSC Norris Comprehensive Cancer Center 90033 Los Angeles United StatesRekrutierend» Google-Maps Ansprechpartner: Anthony El-Khoueiry, MD» Ansprechpartner anzeigenYale Cancer Center 06519 New Haven United StatesRekrutierend» Google-Maps Ansprechpartner: Patricia LoRusso, MD» Ansprechpartner anzeigenUniversity of Miami - Sylvester Comprehensive Cancer Center 33136 Miami United StatesRekrutierend» Google-Maps Ansprechpartner: Gilberto de Lima Lopes Jr., MD» Ansprechpartner anzeigenFlorida Cancer Specialists South 33401 West Palm Beach United StatesNoch nicht rekrutierend» Google-Maps Ansprechpartner: Ivor Percent, MD» Ansprechpartner anzeigenIndiana University 46240 Indianapolis United StatesRekrutierend» Google-Maps Ansprechpartner: Mateusz Opyrchal, MD» Ansprechpartner anzeigenMassachusetts General Hospital 02114 Boston United StatesRekrutierend» Google-Maps Ansprechpartner: Aparna Parikh, MD» Ansprechpartner anzeigenDana Farber Cancer Institute 02215 Boston United StatesRekrutierend» Google-Maps Ansprechpartner: Geoffrey Shapiro, MD, PhD» Ansprechpartner anzeigenKarmanos Cancer Institute 48201 Detroit United StatesRekrutierend» Google-Maps Ansprechpartner: Dipesh Uprety, MD» Ansprechpartner anzeigenRoswell Park Comprehensive Cancer Institute 14203 Buffalo United StatesNoch nicht rekrutierend» Google-Maps Ansprechpartner: Bailey Fitzgerald, MD» Ansprechpartner anzeigenMemorial Sloan Kettering 10065 New York United StatesRekrutierend» Google-Maps Ansprechpartner: Alison Schram, MD» Ansprechpartner anzeigenThe Cleveland Clinic Taussig Cancer Center 44195 Cleveland United StatesRekrutierend» Google-Maps Ansprechpartner: Dale Shepard, MD» Ansprechpartner anzeigenUniversity of Oklahoma 73104 Oklahoma City United StatesRekrutierend» Google-Maps Ansprechpartner: Debra Richardson, MD» Ansprechpartner anzeigenOregon Health & Science University (OHSU) 97210 Portland United StatesRekrutierend» Google-Maps Ansprechpartner: Shivaani Kummar, MD» Ansprechpartner anzeigenAbramson Cancer Center of the University of Pennsylvania 19104 Philadelphia United StatesRekrutierend» Google-Maps Ansprechpartner: Thomas Karasic, MD» Ansprechpartner anzeigenMedical University of South Carolina 29425 Charleston United StatesNoch nicht rekrutierend» Google-Maps Ansprechpartner: John Kaczmar, MD» Ansprechpartner anzeigenSarah Cannon Research Institute 37203 Nashville United StatesRekrutierend» Google-Maps Ansprechpartner: Melissa Johnson, MD» Ansprechpartner anzeigenNew Experimental Therapeutics - NEXT Oncology 78705 Austin United StatesRekrutierend» Google-Maps Ansprechpartner: Anthony Tolcher, MD» Ansprechpartner anzeigenThe University of Texas MD Anderson Cancer Center 77030 Houston United StatesRekrutierend» Google-Maps Ansprechpartner: Escaterina Dumbrava, MD» Ansprechpartner anzeigenNew Experimental Therapeutics of San Antonio - NEXT Oncology 78229 San Antonio United StatesRekrutierend» Google-Maps Ansprechpartner: Anthony Tolcher, MD» Ansprechpartner anzeigenVirginia Cancer Specialists 22031 Fairfax United StatesRekrutierend» Google-Maps Ansprechpartner: Alexander Spira, MD» Ansprechpartner anzeigenUniversity of Washington, Fred Hutchinson Cancer Center 98109 Seattle United StatesRekrutierend» Google-Maps Ansprechpartner: John Thompson, MD» Ansprechpartner anzeigenUniversity of Wisconsin Carbone Cancer Center 53705 Madison United StatesNoch nicht rekrutierend» Google-Maps Ansprechpartner: Nataliya Uboha, MD, PhD» Ansprechpartner anzeigenChris O'Brien Lifehouse Hospital Camperdown AustraliaNoch nicht rekrutierend» Google-Maps Ansprechpartner: Peter Grimison, MD» Ansprechpartner anzeigenMonash Medical Centre Clayton AustraliaNoch nicht rekrutierend» Google-Maps Ansprechpartner: Amy Body, MD» Ansprechpartner anzeigenLinear Clinical Research Nedlands AustraliaNoch nicht rekrutierend» Google-Maps Ansprechpartner: Michael Millward, MD» Ansprechpartner anzeigenICANS - Institut de cancérologie Strasbourg Europe Strasbourg FranceNoch nicht rekrutierend» Google-Maps Ansprechpartner: Lauriane Eberst, MD» Ansprechpartner anzeigenInstitut Bergonie Bordeaux FranceNoch nicht rekrutierend» Google-Maps Ansprechpartner: Antoine Italiano, MD» Ansprechpartner anzeigenInstitut Claudius Regaud Toulouse FranceNoch nicht rekrutierend» Google-Maps Ansprechpartner: Carlos-Alberto Gomez-Roca, MD» Ansprechpartner anzeigenEDOG Institut de Cancerologie de l'Ouest Saint-Herblain FranceNoch nicht rekrutierend» Google-Maps Ansprechpartner: Jean-Sebastien Frenel, MD» Ansprechpartner anzeigenCentre Jean Perrin Clermont-Ferrand FranceNoch nicht rekrutierend» Google-Maps Ansprechpartner: Xavier Durando, MD» Ansprechpartner anzeigenInstitut Gustave Roussy Villejuif FranceNoch nicht rekrutierend» Google-Maps Ansprechpartner: Santiago Ponce Aix, MD» Ansprechpartner anzeigenCentre Léon Bérard Centre Régional de Lutte Contre Le Cancer Lyon FranceNoch nicht rekrutierend» Google-Maps Ansprechpartner: Isabelle Ray-Coquard, MD» Ansprechpartner anzeigenFondazione Policlinico Universitario Agostino Gemelli IRCCS Rome ItalyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Domenica Lorusso, MD» Ansprechpartner anzeigenIstituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena Rome ItalyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Lorenza Landi, MD» Ansprechpartner anzeigenASST Grande Ospedale Metropolitano Niguarda Milano ItalyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Salvatore Siena, MD» Ansprechpartner anzeigenFondazione IRCCS Istituto Nazionale Dei Tumori Milano ItalyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Massimo Di Nicola, MD» Ansprechpartner anzeigenIstituto Europeo Di Oncologia Milano ItalyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Giuseppe Curigliano, MD» Ansprechpartner anzeigenIstituto Clinico Humanitas Rozzano ItalyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Armando Santoro, MD» Ansprechpartner anzeigenFondazione del Piemonte per l'Oncologia (IRCCS) Candiolo ItalyNoch nicht rekrutierend» Google-Maps Ansprechpartner: Vanesa Gregorc, MD» Ansprechpartner anzeigenAsan Medical Center Seoul Korea, Republic ofNoch nicht rekrutierend» Google-Maps Ansprechpartner: Dae Ho Lee, MD» Ansprechpartner anzeigenNational University Hospital Kent Ridge SingaporeNoch nicht rekrutierend» Google-Maps Ansprechpartner: David Shao Peng Tan, MD» Ansprechpartner anzeigenInstituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON Barcelona SpainNoch nicht rekrutierend» Google-Maps Ansprechpartner: Irene Braña, MD» Ansprechpartner anzeigenNEXT Oncology-Hospital Quironsalud Barcelona Barcelona SpainNoch nicht rekrutierend» Google-Maps Ansprechpartner: Elena Garralda, MD» Ansprechpartner anzeigenSTART MADRID_Hospital Universitario Fundacion Jimenez Diaz Madrid SpainNoch nicht rekrutierend» Google-Maps Ansprechpartner: Victor Moreno Garcia, MD» Ansprechpartner anzeigenSTART MADRID_Hospital Universitario HM Sanchinarro - CIOCC Madrid SpainNoch nicht rekrutierend» Google-Maps Ansprechpartner: Maria Jose De Miguel Luken, MD» Ansprechpartner anzeigenHospital Clinico Universitario de Valencia Valencia SpainNoch nicht rekrutierend» Google-Maps Ansprechpartner: Desamparados Roda Perez, MD» Ansprechpartner anzeigenSarah Cannon Research Institute UK London United KingdomNoch nicht rekrutierend» Google-Maps Ansprechpartner: Elisa Fontana, MD, PhD» Ansprechpartner anzeigenRoyal Victoria Infirmary Newcastle Upon Tyne United KingdomNoch nicht rekrutierend» Google-Maps Ansprechpartner: Alastair Greystoke, MB ChB PhD» Ansprechpartner anzeigen
1. Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of PC14586 (INN: rezatapopt) (Time Frame - 40 months): Number of participants with treatment related adverse events
2. Phase 1 Monotherapy (Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) (Time Frame - 30 months): RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data
3. Phase 1 Monotherapy (Dose Escalation): Establish the maximum tolerated dose (MTD) (Phase 1) (Time Frame - The first 28 days of treatment (Cycle 1) per patient): Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with PC14586 (INN: rezatapopt)
4. Phase 1b Combination Therapy (Part 1: Dose Escalation): Determine the number and type of adverse events to characterize the safety of PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (Time Frame - 18 months for treatment arm): Number of participants with treatment related adverse events
5. Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the maximum tolerated dose (MTD) of PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (Time Frame - The first 28 days of combination treatment arm (starting on Day -7) per patient): Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with PC14586 (INN: rezatapopt)
6. Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) of PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (Time Frame - 18 months): RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data
7. Phase 1b Combination Therapy (Part 2: Dose Expansion): Determine the number and type of adverse events to characterize the safety of PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (Time Frame - 12 months for treatment arm): Number of participants with treatment related adverse events
8. Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of PC14586 (INN: rezatapopt) (Time Frame - 34 months): Overall response rate in accordance with Response Evaluation Criteria across all cohorts (RECIST) v.1.1 as assessed by independent review
Secondary outcome:
1. Phase 1 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Peak concentration (Cmax) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
2. Phase 1 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Time of peak concentration (Tmax) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
3. Phase 1 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
4. Phase 1 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Area under the plasma concentration-time curve in one dosing interval (AUCtau) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
5. Phase 1 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Trough observed concentrations (Ctrough/Ctau) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
6. Phase 1 Monotherapy: Blood plasma assessment to describe the concentration of PC14586 and metabolite (M1) when PC14586 (INN: rezatapopt) is administered orally. (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Blood plasma concentration
7. Phase 1 Monotherapy (Dose Escalation): Overall Response Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1 (Time Frame - 41 months for study (end of Phase 1)): Evaluation of preliminary anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
8. Phase 1 Monotherapy (Dose Escalation): Time to Response per RECIST v1.1 or PCWG3 modified RECIST v1.1 (Time Frame - 41 months for study (end of Phase 1)): Evaluation of preliminary anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
9. Phase 1 Monotherapy (Dose Escalation): Duration of Response per RECIST v1.1 or PCWG3 modified RECIST v1.1 (Time Frame - 41 months for study (end of Phase 1)): Evaluation of preliminary anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
10. Phase 1 Monotherapy (Dose Escalation): Disease Control Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1 (Time Frame - 41 months for study (end of Phase 1)): Evaluation of preliminary anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
11. Phase 1 Monotherapy (Dose Escalation): Progression Free Survival per RECIST v1.1 or PCWG3 modified RECIST v1.1 (Time Frame - 41 months for study (end of Phase 1)): Evaluation of preliminary anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
12. Phase 1 Monotherapy (Dose Escalation): Overall Survival (Time Frame - 41 months for study (end of Phase 1)): Evaluation of preliminary anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
13. Phase 1b Combination Therapy: PK profile of PC14586 (INN: rezatapopt) in combination with pembrolizumab - Peak concentration (Cmax) (Time Frame - Approximately 12 months per patient (30 months for treatment arm)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
14. Phase 1b Combination Therapy: PK profile of PC14586 (INN: rezatapopt) in combination with pembrolizumab - Time of peak concentration (Tmax) (Time Frame - Approximately 12 months per patient (30 months for treatment arm)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
15. Phase 1b Combination Therapy: PK profile of PC14586 (INN: rezatapopt) in combination with pembrolizumab - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t) (Time Frame - Approximately 12 months per patient (30 months for treatment arm)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
16. Phase 1b Combination Therapy: PK profile of PC14586 (INN: rezatapopt) in combination with pembrolizumab - Area under the plasma concentration-time curve in one dosing interval (AUCtau) (Time Frame - Approximately 12 months per patient (30 months for treatment arm)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
17. Phase 1b Combination Therapy: PK profile of PC14586 (INN: rezatapopt) in combination with pembrolizumab - Trough observed concentrations (Ctrough/Ctau) (Time Frame - Approximately 12 months per patient (30 months for treatment arm)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
18. Phase 1b Combination Therapy: Blood plasma assessment to describe the concentration of PC14586 (INN: rezatapopt) and metabolite (M1) when PC14586 (INN: rezatapopt) is administered orally in combination with pembrolizumab. (Time Frame - Approximately 12 months per patient (30 months for treatment arm)): Blood plasma concentration
19. Phase 1b Combination Therapy: Overall Response Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review (Time Frame - 30 months for study (end of Phase 1b)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) in combination with pembrolizumab
20. Phase 1b Combination Therapy: Time to Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review (Time Frame - 30 months for study (end of Phase 1b)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) in combination with pembrolizumab
21. Phase 1b Combination Therapy: Duration of Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review (Time Frame - 30 months for study (end of Phase 1b)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) in combination with pembrolizumab
22. Phase 1b Combination Therapy: Disease Control Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review (Time Frame - 30 months for study (end of Phase 1b)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) in combination with pembrolizumab
23. Phase 1b Combination Therapy: Overall Survival (Time Frame - 30 months for study (end of Phase 1b)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) in combination with pembrolizumab
24. Phase 1b Combination Therapy: Determine the number and type of adverse events to characterize the safety of PC14586 (INN: rezatapopt) (Time Frame - 30 months for study (end of Phase 1b)): Number of participants with treatment related adverse events
25. Phase 1b Combination Therapy: Progression Free Survival per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review (Time Frame - 30 months for study (end of Phase 1b)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) in combination with pembrolizumab
26. Phase 2 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Time of peak concentration (Tmax) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
27. Phase 2 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Peak concentration (Cmax) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
28. Phase 2 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
29. Phase 2 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Area under the plasma concentration-time curve in one dosing interval (AUCtau) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
30. Phase 2 Monotherapy: PK profile of PC14586 (INN: rezatapopt) - Trough observed concentrations (Ctrough/Ctau) (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of PC14586 (INN: rezatapopt)
31. Phase 2 Monotherapy: Blood plasma assessment to describe the concentration of PC14586 (INN: rezatapopt) and metabolite (M1) when PC14586 (INN: rezatapopt) is administered orally. (Time Frame - Approximately 12 months per patient (75 months for Phase 1 and Phase 2)): Blood plasma concentration
32. Phase 2 Monotherapy (Dose Expansion): Determine the number and type of adverse events to characterize the safety of PC14586 (INN: rezatapopt) (Time Frame - 34 months for study (end of Phase 2)): Number of participants with treatment related adverse events
33. Phase 2 Monotherapy (Dose Expansion): Overall Response Rate across all cohorts per RECIST v1.1 as assessed by Investigator (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
34. Phase 2 Monotherapy (Dose Expansion): Overall Response Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
35. Phase 2 Monotherapy (Dose Expansion): Time to Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
36. Phase 2 Monotherapy (Dose Expansion): Time to Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
37. Phase 2 Monotherapy (Dose Expansion): Duration of Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
38. Phase 2 Monotherapy (Dose Expansion): Duration of Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
39. Phase 2 Monotherapy (Dose Expansion): Disease Control Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
40. Phase 2 Monotherapy (Dose Expansion): Disease Control Rate across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
41. Phase 2 Monotherapy (Dose Expansion): Progression Free Survival in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
42. Phase 2 Monotherapy (Dose Expansion): Progression Free Survival across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
43. Phase 2 Monotherapy (Dose Expansion): Overall Survival in ovarian cancer cohort (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
44. Phase 2 Monotherapy (Dose Expansion): Overall Survival across all cohorts (Time Frame - 34 months for study (end of Phase 2)): Evaluation of anti-tumor activity of PC14586 (INN: rezatapopt) as a single agent
45. Phase 2 Monotherapy (Dose Expansion): Quality of life assessment (Time Frame - Evaluated at every visit. 34 months for treatment arm (end of Phase 2)): Changes from baseline in quality of life as measured by a validated instrument, for participants 18 and older
Experimental: Phase 1 Monotherapy Dose Escalation Multiple dose levels of daily oral PC14586 (INN: rezatapopt) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 (INN: rezatapopt) to recommend a Phase 2 dose (RP2D).
Experimental: Phase 1b Combination Therapy Dose Escalation, Part 1 Multiple dose levels of daily oral PC14586 (INN: rezatapopt) in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab.
Experimental: Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients.
Experimental: Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients.
Experimental: Phase 2 Monotherapy Dose Expansion, Ovarian Cancer Cohort Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Ovarian Cancer Cohort participants will have locally advanced or metastatic ovarian cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
Experimental: Phase 2 Monotherapy Dose Expansion, Lung Cancer Cohort Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
Experimental: Phase 2 Monotherapy Dose Expansion, Breast Cancer Cohort Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Breast Cancer Cohort participants will have locally advanced or metastatic breast cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
Experimental: Phase 2 Monotherapy Dose Expansion, Endometrial Cancer Cohort Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Endometrial Cancer Cohort participants will have locally advanced or metastatic endometrial cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
Experimental: Phase 2 Monotherapy Dose Expansion, Other Solid Tumors Cohort Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Other Solid Tumors Cohort participants will have locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.